Skip to main content
Erschienen in: Current Cardiology Reports 1/2012

01.02.2012 | Diabetes and Cardiovascular Disease (ND Wong, Section Editor)

Projected and Observed Diabetes Epidemics in China and Beyond

verfasst von: Dong Zhao, Fan Zhao, Yan Li, Zheng Zheng

Erschienen in: Current Cardiology Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Diabetes is one of the major noncommunicable diseases found worldwide. Different researchers have reported the predicted and observed prevalence of diabetes and the number of people with diabetes over different years in China and in other countries. This review provides a new insight into the growing epidemic of diabetes in recent decades and in the coming future by comparing projected and observed prevailing trends of this disease reported in the international literature. The review found that the projected burden of diabetes for China in each time point from 2000 to 2030 underestimated the epidemic of diabetes in terms of the prevalence and the total number of people with the disease. Based on a recent Chinese national survey, the observed prevalence and the total number of people with diabetes in 2008 (9.7% and 92.4 million, respectively) were remarkably higher than that expected for 2009 or 2010 (3.9% and 53.1 million for 2009, and 4.5% and 43.2 million for 2010).The observed 2008 figures were even much higher than the projected prevalence and the number of people with diabetes for 2030. The tendency to underestimate future diabetes epidemics also occurs in many other countries, especially those characterized by low and middle incomes.
Literatur
1.
Zurück zum Zitat Saundby R. Diabetes mellitus among the Chinese. Br Med J. 1908;1:116.CrossRef Saundby R. Diabetes mellitus among the Chinese. Br Med J. 1908;1:116.CrossRef
2.
Zurück zum Zitat National Diabetes Research Group. A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China (author’s transl). Zhonghua Nei Ke Za Zhi. 1981;11:678–83. National Diabetes Research Group. A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China (author’s transl). Zhonghua Nei Ke Za Zhi. 1981;11:678–83.
3.
Zurück zum Zitat Hu YH, Li GW, Pan XR. Incidence of NIDDM in Daqing and forecasting of NIDDM in China in 21st century. Zhonghua Nei Ke Za Zhi. 1993;32(3):173–5.PubMed Hu YH, Li GW, Pan XR. Incidence of NIDDM in Daqing and forecasting of NIDDM in China in 21st century. Zhonghua Nei Ke Za Zhi. 1993;32(3):173–5.PubMed
4.
Zurück zum Zitat • Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. This paper predicted the worldwide prevalence rates and number of patients with diabetes in 2010 and 2030. PubMedCrossRef • Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. This paper predicted the worldwide prevalence rates and number of patients with diabetes in 2010 and 2030. PubMedCrossRef
5.
Zurück zum Zitat Pan XR, Yang WY, Li GW, Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care. 1997;20(11):1664–9.PubMedCrossRef Pan XR, Yang WY, Li GW, Liu J. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care. 1997;20(11):1664–9.PubMedCrossRef
6.
Zurück zum Zitat Wang K, Li T, Xiang H, Liu Z, Bai J, Feng J, et al. Study on the epidemiological characteristics of diabetes mellitus and IGT in China. Zhong Guo Liu Xing Bing Xue Za Zhi. 1998;19(5):282–5. Wang K, Li T, Xiang H, Liu Z, Bai J, Feng J, et al. Study on the epidemiological characteristics of diabetes mellitus and IGT in China. Zhong Guo Liu Xing Bing Xue Za Zhi. 1998;19(5):282–5.
7.
Zurück zum Zitat Pan C. Diabetes care in China: meeting the challenge. World Hosp Health Serv. 2005;41(3):29–30. 2.PubMed Pan C. Diabetes care in China: meeting the challenge. World Hosp Health Serv. 2005;41(3):29–30. 2.PubMed
8.
Zurück zum Zitat • Pan C, Shang S, Kirch W, Thoenes M. Burden of diabetes in the adult Chinese population: a systematic literature review and future projections. Int J Gen Med. 2010;3:173–9. This paper estimated and predicted the prevalence rates of diabetes in China for 2009 and 2016. PubMed • Pan C, Shang S, Kirch W, Thoenes M. Burden of diabetes in the adult Chinese population: a systematic literature review and future projections. Int J Gen Med. 2010;3:173–9. This paper estimated and predicted the prevalence rates of diabetes in China for 2009 and 2016. PubMed
9.
Zurück zum Zitat Liu S, Wang W, Zhang J, He Y, Yao C, Zeng Z, et al. Prevalence of diabetes and impaired fasting glucose in Chinese adults, China National Nutrition and Health Survey, 2002. Prev Chronic Dis. 2011;8(1):A13.PubMed Liu S, Wang W, Zhang J, He Y, Yao C, Zeng Z, et al. Prevalence of diabetes and impaired fasting glucose in Chinese adults, China National Nutrition and Health Survey, 2002. Prev Chronic Dis. 2011;8(1):A13.PubMed
10.
Zurück zum Zitat Department of Population, Social, Science and Technology Statistics National Bureau of Statistics of China. China population statistics yearbook. Beijing: China Statistics Press; 2003. Department of Population, Social, Science and Technology Statistics National Bureau of Statistics of China. China population statistics yearbook. Beijing: China Statistics Press; 2003.
11.
Zurück zum Zitat • Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101. This is the most recent survey for prevalence of diabetes and prediabetes in China. PubMedCrossRef • Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101. This is the most recent survey for prevalence of diabetes and prediabetes in China. PubMedCrossRef
12.
Zurück zum Zitat King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.PubMedCrossRef King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.PubMedCrossRef
13.
Zurück zum Zitat Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.PubMedCrossRef Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.PubMedCrossRef
14.
Zurück zum Zitat Jia WP, Pang C, Chen L, Bao YQ, Lu JX, Lu HJ, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50(2):286–92.PubMedCrossRef Jia WP, Pang C, Chen L, Bao YQ, Lu JX, Lu HJ, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50(2):286–92.PubMedCrossRef
15.
Zurück zum Zitat Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, et al. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovasc Ther. 2010;28(2):124–32.PubMedCrossRef Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, et al. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovasc Ther. 2010;28(2):124–32.PubMedCrossRef
16.
Zurück zum Zitat Liu J, Grundy SM, Wang W, Smith Jr SC, Vega GL, Wu Z, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J. 2007;153(4):552–8.PubMedCrossRef Liu J, Grundy SM, Wang W, Smith Jr SC, Vega GL, Wu Z, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J. 2007;153(4):552–8.PubMedCrossRef
17.
Zurück zum Zitat International Diabetes Federation. Diabetes atlas, 3rd edn. Diabetes and Impaired Glucose Tolerance. 2006. International Diabetes Federation. Diabetes atlas, 3rd edn. Diabetes and Impaired Glucose Tolerance. 2006.
18.
Zurück zum Zitat Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–32.PubMed Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–32.PubMed
19.
20.
Zurück zum Zitat Fu P, Man Q, Zhang J, Wang C. Epidemiological study on diabetes mellitus in Chinese children and adolescents at the age of 5 to 17 years. Wei Sheng Yan Jiu. 2007;36(6):722–4.PubMed Fu P, Man Q, Zhang J, Wang C. Epidemiological study on diabetes mellitus in Chinese children and adolescents at the age of 5 to 17 years. Wei Sheng Yan Jiu. 2007;36(6):722–4.PubMed
21.
Zurück zum Zitat Liu W, Lin R, Liu A, Du L, Chen Q. Prevalence and association between obesity and metabolic syndrome among Chinese elementary school children: a school-based survey. BMC Publ Health. 2010;10:780.CrossRef Liu W, Lin R, Liu A, Du L, Chen Q. Prevalence and association between obesity and metabolic syndrome among Chinese elementary school children: a school-based survey. BMC Publ Health. 2010;10:780.CrossRef
Metadaten
Titel
Projected and Observed Diabetes Epidemics in China and Beyond
verfasst von
Dong Zhao
Fan Zhao
Yan Li
Zheng Zheng
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 1/2012
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-011-0227-9

Weitere Artikel der Ausgabe 1/2012

Current Cardiology Reports 1/2012 Zur Ausgabe

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Low-Dose Cardiovascular Computed Tomography: Where are the Limits?

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to Practice

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

The Prognostic Significance of Coronary CT Angiography

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Cardiac PET, CT, and MR: What Are the Advantages of Hybrid Imaging?

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

Promise of Factor Xa Inhibition in Acute Coronary Syndromes

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.